TIBOLA : Multicenter Descriptive Study in Eastern France
1 other identifier
observational
20
1 country
2
Brief Summary
TIBOLA (TIck-BOrne LymphAdenopathy) is a tick-borne disease. The pathogen is most often rickettsia (R. slovaca or R. raoultii), but other strict intracellular bacteria have been described (Francisella tularensis, Coxiella burnetii, Bartonella hensenlae). Transmitted by ticks (Dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. It is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia. In spring 2021, an impression of increased cases was reported by clinicians in Eastern France. The study aims to clarify the clinical-biological presentation and the evolution of the number of cases of TIBOLA in this region between 2016 and 2021. At the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2022
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2022
CompletedFirst Submitted
Initial submission to the registry
July 11, 2022
CompletedFirst Posted
Study publicly available on registry
July 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2023
CompletedJuly 19, 2022
July 1, 2022
7 months
July 11, 2022
July 15, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of cases of TIBOLA
baseline
Secondary Outcomes (6)
Epidemiological and demographic characteristics
baseline
Characteristics of tick bites
baseline
Frequency of the various symptoms and clinical signs of the disease
baseline
Biological results
baseline
Treatment
baseline
- +1 more secondary outcomes
Eligibility Criteria
* Definite case: clinically compatible (inoculation eschar with locoregional adenopathy(s) +/- general signs) +/- tick bite noted AND microbiological proof (positive PCR or seroconversion for a microorganism responsible for TIBOLA) OR * Probable case: clinically compatible (inoculation eschar with locoregional adenopathy(s) +/- general signs) AND tick bite noted without microbiological proof.
You may qualify if:
- Person, minor or major,
- having been diagnosed with TIBOLA
- between January 1, 2016 and December 31, 2021
- at the University Hospital of Nancy or Strasbourg in the departments of infectious and tropical diseases, dermatology, microbiology and pediatrics.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Yves Hansmann
Strasbourg, 67000, France
Elisabeth Baux
Vandœuvre-lès-Nancy, 54500, France
Related Publications (1)
Kotzyba J, Baux E, Hansmann Y, Boyer P, Jaulhac B, Martinot M, Martha B, Kaeuffer C, Bonijoly T, Bani-Sadr F, Legoff A, Hoefler F, Blot M, Bourdellon L, Zilliox L, Boulanger N, Lefevre B. Tick-borne lymphadenopathy in northeastern France: a human and vector clinical-epidemiological study. Parasit Vectors. 2025 Oct 24;18(1):428. doi: 10.1186/s13071-025-07078-2.
PMID: 41137175DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 11, 2022
First Posted
July 14, 2022
Study Start
June 1, 2022
Primary Completion
January 1, 2023
Study Completion
June 1, 2023
Last Updated
July 19, 2022
Record last verified: 2022-07